Site map
العربية Български 中文 Čeština English Français Deutsch हिन्दी Bahasa Indonesia Italiano Bahasa Malay اردو Polski Português Română Русский Srpski Slovenský Español ไทย Nederlands Українська Vietnamese বাংলা Ўзбекча O'zbekcha Қазақша

InstaForex Client Area

  • Personal settings
  • Access to all InstaForex services
  • Detailed statistics and reports on trades
  • Full range of financial transactions
  • System of managing several accounts
  • Maximum data protection

InstaForex Partner Area

  • Full information on clients and commissions
  • Graphic statistics on accounts and clicks
  • Webmaster instruments
  • Ready-made web solutions and wide range of banners
  • High data protection level
  • Company's news, RSS feeds, and forex informers
Register
cabinet icon

InstaForex – always at the forefront!Open a trading account and become a part of the InstaForex Loprais Team!

Success history of the team headed by Ales Loprais can become your success history! Trade confidently and head towards leadership like regular participant of Dakar Rally and winner of Silk Way Rally InstaForex Loprais Team does it!

Join in and win with InstaForex!

Instant account opening

Get a letter of instructions
toolbar icon

Trading Platform

For mobile devices

For trading via browser

ব্যঙ্গাত্মক বর্ণনা এবং ফরেক্সের প্রবেশদ্বার বিন্যাস

Gilead Sciences to charge $390 for its coronavirus drug

Gilead Sciences to charge $390 for its coronavirus drug

It seems that in the race for the COVID-19 fighting drug, the US will be the first. Gilead, the US research-based biopharmaceutical company, announced that the European Commission had granted marketing authorization to Veklury (remdesivir) as a treatment for COVID-19. Notably, the company also said it would sell the drug to developed countries for a much lower price in order to create a one-price model. Gilead did not clarify the price for developing countries and third world countries. In an open letter to the authorities of developed countries on behalf of the CEO and Chairman of the Board of Directors of Gilead, Daniel O’Day, said that it would charge $390 per vial for its drug.

This drug has been successfully tested. According to the data, the average patient infected with the coronavirus should undergo a five-day course of treatment, which includes six vials of remdesivir. The company set the price for developed countries at $2,340. Private clinics, insurance companies, and other entities will be able to buy remdesivir for $520 per vial, or $3,120 for a five-day course.

"In normal circumstances, we would price a medicine according to the value it provides. We have decided to price remdesivir well below this value. To ensure broad and equitable access at a time of urgent global need, we have set a price for governments of developed countries of $390 per vial", Daniel O’Day said in an open letter. "The first results from the NIAID study in hospitalized patients with COVID-19 showed that remdesivir shortened time to recovery by an average of four days. Taking the example of the United States, earlier hospital discharge would result in hospital savings of approximately $12,000 per patient,” he added.


পিছনে

See aslo


বন্ধ
Widget calback
আমাদের বিশেষজ্ঞগণ
আপনাকে পাঁচ মিনিটের মধ্যে
কল করবে
ওয়েবসাইটের মাধ্যমে আমরা
আপনার কার্যক্রম পর্যালোচনা করব এবং
আপনার সকল প্রশ্নের জবাব দিব!
পছন্দের সংযোগের ধরণ
পছন্দের ভাষা
  • English
  • Русский
  • العربية
  • Bahasa Indonesia
  • Bahasa Melayu
  • বাংলা
  • Български
  • 中文
  • Español
  • हिन्दी
  • Asụsụ Igbo
  • Português
  • اردو
  • ไทย
  • Українська
  • Tiếng Việt
  • Èdè Yorùbá
একটি কলব্যাক অনুরোধ গ্রহণ করা হয়েছে।
আমাদের বিশেষজ্ঞগণ যত দ্রুত সম্ভব আপনার সাথে যোগাযোগ করবে।
ভুল হয়েছে।
দয়াকরে আবার চেষ্টা করুন।
এখন কথা বলতে পারবেন না?
আপনার প্রশ্ন জিজ্ঞাসা করুন চ্যাট.